Fresenius Se & Co. Kgaa · XETR:FRE
Fresenius Se & Co. Kgaa — Merger or Acquisition (April 2012)
13 slides from Fresenius Se & Co. Kgaa's merger presentation, Apr 26, 2012
Slide 1: Offer to Acquire All Outstanding Shares of Rhön-Klinikum AG
Offer to Acquire All Outstanding Shares of Rhön-Klinikum AG Conference Call, April 26, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement This announcement is neither an offer to purchase nor a solicitation of an offer to sell RK AG shares. The final terms and further provisions regarding the public offer will be disclosed in the offer document after the publication has been approved by the German Federal Financi
Slide 3: Transaction Highlights
Transaction Highlights - Rhön-Klinikum – a leading German hospital operator - Successful, well-established company with proven track record in patient care - Perfect strategic and geographic fit to create a countrywide hospital network – 75% of the German population have access to a HELIOS- Rhön hos
Slide 4: Rhön-Klinikum at a Glance
Rhön-Klinikum at a Glance Business Overview Financial Track Record - Founded in 1973 Sales EBITDA/margin - 53 hospitals and 39 medical care 2,629 12.8 % centers (MVZ) 338 11.4 % €m - ~16,000 beds, ~2.3 million treatments 1,933 p.a., thereof ~0.7 million in inpatient 221 acute care - >39,000 employee
Slide 5: Perfect Strategic and Geographic Fit – Combined German-wide Hospital Network Pro Forma
Perfect Strategic and Geographic Fit – Combined German-wide Hospital Network Pro Forma - Creating a ~€6 bn hospital provider in 2012 with EBITDA of >€750m1 - 75% of the German population have access to a hospital of the combined organization within one hour’s drive - 1 university hospital, 7 maximum
Slide 6: Unlocking Synergies Across Both Organizations
Unlocking Synergies Across Both Organizations Time Effect Bundle procurement – double volumes Procurement/Services Yr 1 – 2 Combine services, e.g. catering, cleaning, laundry Administration/ Combine HELIOS’ and Rhön-Klinikum’s Yr 1 Overhead administration Improve hospital portfolio in line with Yr 1
Slide 7: Perfect Strategic Fit – Sources for Future Growth
Perfect Strategic Fit – Sources for Future Growth German-wide Hospital Network as a Key Prerequisite Time Effect Selective approach due to broad regional presence; Privatization Revenue target of ~€150 million p.a. (multi-year- Opportunities average) for combined organization, effectively cutting gr
Slide 8: Key Transaction Terms
Key Transaction Terms - €22.50 per share in cash for each outstanding share of Rhön-Klinikum Offer - Equity value at €3.1 bn - Increase of offering price not planned - 52% premium to €14.77, Rhön-Klinikum’s Xetra close on April 25, 2012 Implied Premium - 53% premium to €14.73, Rhön-Klinikum’s 3-mont
Slide 9: Financial Impact
Financial Impact - Fully committed by leading banks - Financing through credit facilities, senior notes, and equity instruments in the amount of up to €1 bn Financing - No financing through FMC shares - Sufficient financial cushion to allow for ongoing small/mid-sized acquisitions - Net debt/EBITDA
Slide 10: Fresenius Group: Financial Outlook by Business Segment Fully Confirmed or Raised
Fresenius Group: Financial Outlook by Business Segment Fully Confirmed or Raised Previous Q1/12 New Guidance Achievements Guidance Fresenius Sales growth1 4% – 6% 11% 6% – 8% Kabi EBIT margin 19.5% – 20% 19.7% upper end of range Fresenius Sales growth1 3% – 5% 5% confirmed Helios EBIT €310 – €320 m
Slide 11: Fresenius Group: Financial Outlook Raised
Fresenius Group: Financial Outlook Raised Previous Q1/12 New Guidance Achievements Guidance Revenue growth 10% – 13% 10% upper end at constant currency of range Net income growth1 8% – 11% 15% 12% – 15% at constant currency Capex ~5% of ~3% confirmed Group sales 1 Net income attributable to sharehol
Slide 12: Share Information
Share Information Share key facts Number of shares1 163,334,670 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Exchange OTC-market Structure
Slide 13: Financial Calendar
Financial Calendar 03.05.2012 Report on 1st quarter 2012 11.05.2012 Annual General Meeting, Frankfurt/Main 01.08.2012 Report on 1st half 2012 31.10.2012 Report on 1st – 3rd quarter 2012 Contact Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: Birgit.Gr
Fresenius SE & Co. KGaA — Merger or Acquisition (April 2012) on 6ix